Medicus Pharma Ltd.(MDCX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MDCX Medicus Pharma Ltd.

已收盘 07-24 16:00:00 EDT

0.3700

-0.0142

-3.70%

盘后0.3706

+0.0006+0.16%

19:53 EDT

最高0.4174	最低0.3700	成交量103.23万
今开0.3906	昨收0.3842	日振幅12.34%
总市值2,096万	流通市值1,806万	总股本5,666万
成交额40.86万	换手率2.11%	流通股本4,882万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.37,"timestamp":1784923200000,"preClose":0.3842,"halted":0,"volume":1032268,"hourTrading":{"tag":"盘后","latestPrice":0.3706,"preClose":0.37,"latestTime":"19:53 EDT","volume":33998,"amount":12864.1342,"timestamp":1784937227280,"change":0.0006,"changeRate":0.001622,"amplitude":0.081081},"delay":0,"changeRate":-0.03695991671004683,"floatShares":48821600,"shares":56658200,"eps":-2.63,"marketStatus":"已收盘","change":-0.0142,"latestTime":"07-24 16:00:00 EDT","open":0.3906,"high":0.4174,"low":0.37,"amount":408605.60504916,"amplitude":0.123373,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.63,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":5,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.3842,"preHourTrading":{"tag":"盘前","latestPrice":0.3832,"preClose":0.3842,"latestTime":"09:09 EDT","volume":5685,"amount":2153.3321229,"timestamp":1784898584754,"change":-0.001,"changeRate":-0.002603,"amplitude":0.03696},"postHourTrading":{"tag":"盘后","latestPrice":0.3706,"preClose":0.37,"latestTime":"19:53 EDT","volume":33998,"amount":12864.1342,"timestamp":1784937227280,"change":0.0006,"changeRate":0.001622,"amplitude":0.081081},"volumeRatio":1.434599},"requestUrl":"/m/hq/s/MDCX","defaultTab":"news","newsList":[{"id":"1153699376","title":"Medicus Pharma获FDA积极反馈及中心IRB批准，开展优化版Teverelix®治疗急性尿潴留二期新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1153699376","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153699376?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:31","pubTimestamp":1784201518,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布，其针对急性尿潴留的优化版Teverelix®二期新研究已获得美国食品药品监督管理局（FDA）的积极反馈以及中心机构审查委员会（IRB）的批准。这一关键进展标志着该创新疗法向临床开发迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126634681","title":"Medicus Pharma宣布向美国食品药品监督管理局提交Skinject®用于戈林综合征的罕见儿科疾病认定申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1126634681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126634681?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:31","pubTimestamp":1781523074,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（MDCX）已正式向美国食品药品监督管理局（FDA）提交申请，为其在研产品Skinject®寻求戈林综合征适应症的罕见儿科疾病认定。这一认定若获批准，将有望为患有此种罕见遗传性皮肤疾病的儿童患者带来新的治疗希望，并可能使公司在后续的研发与商业化进程中享有相应的政策激励。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110064382","title":"Medicus Pharma推进Teverelix®项目进入注册开发阶段，针对高心血管风险前列腺癌患者完成关键欧洲提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1110064382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110064382?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:33","pubTimestamp":1780918414,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已将其Teverelix项目推进至注册开发阶段，旨在针对伴有高心血管风险的前列腺癌患者。这一进展的关键标志是公司已向欧洲监管机构提交了关键文件。Teverelix项目专注于满足这一特定患者群体的医疗需求，他们因心血管并发症风险较高，在治疗选择上面临更大挑战。下一步，公司将与监管机构密切合作，以确定后续的开发路径。这一战略举措有望为Medicus Pharma在该治疗领域建立重要地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113733033","title":"Medicus Pharma公布预设扩展二期Sknjct-003数据分析结果 显示显著剂量效应","url":"https://stock-news.laohu8.com/highlight/detail?id=1113733033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113733033?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:37","pubTimestamp":1778067449,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.最新披露的预设扩展二期临床试验Sknjct-003数据分析结果证实，其研究药物存在明确的剂量-效应关系。该数据进一步验证了治疗方案的有效性，为后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107238761","title":"Medicus Pharma Ltd. 旗下D-Mna展现良好安全性特征 未出现药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107238761","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107238761?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:34","pubTimestamp":1778067254,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日公布其研究药物D-Mna的临床试验数据，结果显示该药物表现出良好的安全性特征。在整个试验过程中，未观察到任何与药物相关的严重不良事件。\n这一积极数据为D-Mna的后续临床开发奠定了坚实基础，凸显了其在安全性方面的显著优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169937282","title":"Medicus制药公司提交SEC文件：拟通过代理机构发行不超过5000万美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1169937282","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169937282?lang=zh_cn&edition=full","pubTime":"2026-04-24 05:13","pubTimestamp":1776978807,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Medicus制药有限公司计划通过指定代理机构，以公开发行的方式出售普通股，募集资金总额最高可达5000万美元。\n该文件表明，公司可能根据市场条件、股价波动等因素，一次或分多次进行股份发售。此次融资方案将为Medicus制药提供额外的运营资本，以支持其业务发展和战略计划的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128375198","title":"Medicus Pharma向美国FDA提交Skinject®治疗基底细胞痣综合征的孤儿药认定申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1128375198","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128375198?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:34","pubTimestamp":1776425694,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. (MDCX) 已正式向美国食品药品监督管理局（FDA）提交申请，为其创新药物Skinject®寻求孤儿药认定，适应症为基底细胞痣综合征（Gorlin Syndrome）。\n此举标志着该公司在推进该罕见病治疗方案方面迈出了关键一步。孤儿药认定旨在激励针对影响少数人群的罕见疾病的药物研发。若获得批准，将为Skinject®后续的临床开发及商业化带来潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176135876","title":"Medicus医药公司向美国FDA提交Teverelix治疗急性尿潴留的优化二期研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1176135876","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176135876?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:31","pubTimestamp":1775475075,"startTime":"0","endTime":"0","summary":"Medicus医药公司（Medicus Pharma Ltd.）已向美国食品药品监督管理局（FDA）提交了其候选药物Teverelix用于治疗急性尿潴留的优化二期临床试验方案。此举标志着该药物在临床开发路径上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111663718","title":"Medicus Pharma：二期研究为“概念验证”探索性研究，主要聚焦实现显著临床（视觉）清除","url":"https://stock-news.laohu8.com/highlight/detail?id=1111663718","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111663718?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:33","pubTimestamp":1775043222,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近期公布，其二期研究定位为一项“概念验证”性质的探索性研究。该研究的核心目标在于实现具有临床意义的视觉清除效果，为后续开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160017302","title":"Medicus Pharma业务更新电话会议将重点展示Skinject二期研究80%总体缓解率及AI驱动药物开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1160017302","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160017302?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:31","pubTimestamp":1774524676,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.即将召开业务更新电话会议，届时将重点公布其Skinject二期临床研究取得的突破性进展——该试验显示出高达80%的总体缓解率。此外，公司还将详细介绍其基于Agentic人工智能技术的药物开发战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128433525","title":"Medicus医药公司宣布皮肤注射剂二期首席研究员兼意见领袖Babar K. Rao博士将于3月26日业务更新网络直播中解读积极临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1128433525","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128433525?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:32","pubTimestamp":1773660769,"startTime":"0","endTime":"0","summary":"Medicus医药公司近日宣布，其皮肤疾病治疗产品Skinject®二期临床试验的首席研究员兼关键意见领袖Babar K. Rao博士（医学博士、美国皮肤科学院院士）将于3月26日的业务更新网络直播中对最新阳性数据进行临床解读。此次直播将深入解析试验数据的临床意义与价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953047","title":"Siga Technologies Inc.盘中异动 股价大跌5.17%报5.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953047","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618953047?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:00","pubTimestamp":1773064835,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日22时00分，Siga Technologies Inc.股票出现波动，股价急速下挫5.17%。截至发稿，该股报5.50美元/股，成交量7.3733万股，换手率0.10%，振幅3.28%。Siga Technologies Inc.股票所在的制药行业中，整体跌幅为0.82%。Siga Technologies Inc.公司简介：西佳科技有限公司是一家专注于健康安全市场的商业阶段制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030922003695461cf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030922003695461cf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","SIGA","BK4139","BK4583","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617658389","title":"Prf Technologies Ltd.盘中异动 急速跳水8.00%报2.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617658389?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:59","pubTimestamp":1772809178,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日22时59分，Prf Technologies Ltd.股票出现异动，股价急速跳水8.00%。截至发稿，该股报2.53美元/股，成交量2434股，换手率0.31%，振幅4.91%。Prf Technologies Ltd.股票所在的制药行业中，整体跌幅为1.85%。Prf Technologies Ltd.公司简介：PainReform Ltd是一家多元化的平台型企业，涵盖特种制药、药物输送技术以及基于人工智能的可再生能源分析等领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306225938a6ab4be6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306225938a6ab4be6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRFX","MDCX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177064497","title":"Medicus Pharma公布二期Sknjct-003试验积极顶线数据：200微克组第57天实现73%临床清除率与40%组织学清除率","url":"https://stock-news.laohu8.com/highlight/detail?id=1177064497","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177064497?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:33","pubTimestamp":1772714036,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.近日披露了其二期临床试验Sknjct-003的顶线研究结果，数据表现亮眼。在200微克剂量组中，第57天的评估显示，患者达到73%的临床清除率，同时组织学清除率也达到40%。这一数据为后续临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613518237","title":"美国OTC市场Gsk Plc盘中异动 股价大跌5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613518237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613518237?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:51","pubTimestamp":1771858316,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时51分，美国OTC市场Gsk Plc股票出现波动，股价急速跳水5.77%。截至发稿，该股报29.40美元/股，成交量970股，换手率0.00%，振幅0.00%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。美国OTC市场Gsk Plc股票所在的制药行业中，整体涨幅为1.91%。美国OTC市场Gsk Plc公司简介：在制药行业，葛兰素史克是总销售额最大的公司之一。葛兰素史克利用合资企业在艾滋病毒等特定市场获得额外的规模。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232251569541aee0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232251569541aee0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","GLAXF","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613398217","title":"Medicus Pharma Ltd.盘中异动 下午盘大幅拉升5.45%报1.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613398217","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613398217?lang=zh_cn&edition=full","pubTime":"2026-02-21 04:03","pubTimestamp":1771617797,"startTime":"0","endTime":"0","summary":"北京时间2026年02月21日04时03分，Medicus Pharma Ltd.股票出现波动，股价急速拉升5.45%。Medicus Pharma Ltd.股票所在的制药行业中，整体跌幅为0.71%。Medicus Pharma Ltd.公司简介：Medicus Pharma Ltd是一家临床阶段的控股公司，专注于通过经美国食品药品监督管理局批准的临床试验，投资和推动新型生命科学和生物技术公司的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022104031797a6970e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022104031797a6970e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610232921","title":"Medicus Pharma Ltd.盘中异动 急速下跌5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610232921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610232921?lang=zh_cn&edition=full","pubTime":"2026-02-11 23:01","pubTimestamp":1770822106,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日23时01分，Medicus Pharma Ltd.股票出现异动，股价快速跳水5.83%。Medicus Pharma Ltd.股票所在的制药行业中，整体涨幅为0.03%。Medicus Pharma Ltd.公司简介：Medicus Pharma Ltd是一家临床阶段的控股公司，专注于通过经美国食品药品监督管理局批准的临床试验，投资和推动新型生命科学和生物技术公司的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211230147a6ef7f82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211230147a6ef7f82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179126983","title":"Medicus Pharma获FDA批准Teverelix®针对高心血管风险晚期前列腺癌患者的IIb期研究可继续进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1179126983","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179126983?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:30","pubTimestamp":1770726624,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 宣布，其用于治疗伴有高心血管风险的晚期前列腺癌患者的Teverelix® IIb期临床试验，已获得美国食品药品监督管理局（FDA）的“研究可继续进行”许可。这一监管里程碑意味着公司可以按计划推进该临床阶段的研究工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184034229","title":"Medicus Pharma Ltd.修订协议未改变授权范围、核心知识产权及双方开发职责","url":"https://stock-news.laohu8.com/highlight/detail?id=1184034229","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184034229?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:33","pubTimestamp":1769085202,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日宣布，其对现有协议的修订并未对原授权协议的范围、基础知识产权归属或合作双方各自的开发责任产生任何实质性改变。此次修订旨在优化合作条款，确保项目推进效率，同时维持原有知识产权框架与开发义务的稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127677442","title":"Medicus Pharma Ltd. 宣布修订Lifearc许可协议，优化Teverelix®长期经济与开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1127677442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127677442?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:31","pubTimestamp":1769085098,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已宣布对其与Lifearc达成的许可协议进行修订。此次修订旨在显著提升其核心产品Teverelix®的长期经济价值和开发潜力。协议的调整预计将为该药物的未来商业化道路带来更有利的条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medicuspharma.com","stockEarnings":[{"period":"1week","weight":-0.0537},{"period":"1month","weight":-0.1556},{"period":"3month","weight":0.2201},{"period":"6month","weight":-0.7196},{"period":"1year","weight":-0.874},{"period":"ytd","weight":-0.7489}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Medicus Pharma Ltd.于2008年4月30日根据加拿大安大略省法律成立。该公司是一家处于临床阶段的多战略生物技术/生命科学公司，专注于投资和加速新型和潜在颠覆性治疗资产的临床开发项目。该公司研究了所有治疗领域的机会，这些领域存在未满足的需求，需要提高患者的安全性和疗效。该公司正在机会主义地探索通过合格和增值的收购和合作来扩大其药物开发渠道。","exchange":"NASDAQ","name":"Medicus Pharma Ltd.","nameEN":"Medicus Pharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Medicus Pharma Ltd.(MDCX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Medicus Pharma Ltd.(MDCX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Medicus Pharma Ltd.,MDCX,Medicus Pharma Ltd.股票,Medicus Pharma Ltd.股票老虎,Medicus Pharma Ltd.股票老虎国际,Medicus Pharma Ltd.行情,Medicus Pharma Ltd.股票行情,Medicus Pharma Ltd.股价,Medicus Pharma Ltd.股市,Medicus Pharma Ltd.股票价格,Medicus Pharma Ltd.股票交易,Medicus Pharma Ltd.股票购买,Medicus Pharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Medicus Pharma Ltd.(MDCX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Medicus Pharma Ltd.(MDCX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}